Philip Morris Boosts FY21 Earnings Outlook - Quick Facts

While reporting financial results for the first quarter on Tuesday, Philip Morris International Inc. (PM) raised its earnings guidance for the full-year 2021 to a range of $5.93 to $6.03 per share from the prior range of $5.90 to $6.00 per share.

This represents organic adjusted earnings growth of 11 to 13 percent to a range of $5.75 to $5.85 per share, reflecting net revenue growth of 5 to 7 percent on the same basis, compared to a range of about 4 to 7 percent previously.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $5.95 per share on revenue growth of 8.1 percent to $31.01 billion for the year. Analysts' estimates typically exclude special items.

The company also projected heated tobacco unit shipment volume of 95 to 100 billion units, compared to a range of 90 to 100 billion units previously.

For the second quarter, this outlook represents earnings in a range of $1.50 to $1.55 per share, including a favorable currency impact, at prevailing exchange rates, of around $0.04 per share. The Street is currently looking for earnings of $1.53 per share for the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
CVS Health is set to recruit qualified candidates to fill 25,000 clinical and retail jobs during a one-day national career event on Friday, September 24. This will enable CVS to meet the high demand for pharmacists, pharmacy technicians, nurses, and retail store associates to support flu season, COVID-19 vaccinations and testing. Twitter, Inc. (TWTR) announced Monday that it has entered into a binding agreement to settle the consolidated class action lawsuit commenced in 2016 in the United States District Court for the Northern District of California. Under the terms of the proposed settlement, Twitter will pay $809.5 million... Drug major Pfizer has again expanded the earlier two recalls of its anti-smoking Drug Chantix (Varenicline) in the form of tablets, to now include all the lots, for the potential presence of nitrosamine impurity, N-Nitroso- varenicline, at or above the FDA interim acceptable intake limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement.
Follow RTT